Literature DB >> 24310794

Identification of pro- and anti-proliferative oligosaccharides of heparins.

Qi Ying Lean1, Rahul P Patel, Niall Stewart, Sukhwinder Singh Sohal, Nuri Gueven.   

Abstract

Heparins, unfractionated heparin (UFH) and low molecular weight heparins (LMWHs), are heterogeneous mixtures of anticoagulant and non-anticoagulant oligosaccharides. In addition to their well-known anticoagulant effect, heparins have shown to mediate a wide range of non-anticoagulant effects, including the modulation of cellular growth. However, contradictory results have been reported with regard to their effects on cellular proliferation, with some studies suggesting anti-proliferative while others indicating pro-proliferative effects. This study investigated the proliferation of human colonic epithelial cancer cells in the presence of UFH and LMWHs (enoxaparin and dalteparin). In our experimental setting, all heparins caused a dose-dependent reduction in cellular growth, which correlated well with the induction of cell cycle arrest in the G₁ phase and which was not associated with significant changes in cell viability. The effects on cellular proliferation of 14 different oligosaccharides of enoxaparin obtained through ion-exchange chromatography were also assessed. Surprisingly, only two oligosaccharides showed distinctive anti-proliferative effects while the majority of oligosaccharides actually stimulated proliferation. Interestingly, the smallest oligosaccharide devoid of any anticoagulant activity showed the strongest anti-proliferative effect. Notably, heparins are currently standardised only according to their anticoagulant activity but not based on other non-anticoagulant properties. Our results indicate that slight differences in the composition of heparins' non-anticoagulant oligosaccharides, due to different origins of material and preparation methods, have the potential to cause diverse effects and highlight the need for additional characterisation of non-anticoagulant activities.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24310794     DOI: 10.1039/c3ib40206a

Source DB:  PubMed          Journal:  Integr Biol (Camb)        ISSN: 1757-9694            Impact factor:   2.192


  4 in total

Review 1.  Low molecular weight heparin and cancer survival: clinical trials and experimental mechanisms.

Authors:  Ning Zhang; Weihua Lou; Fang Ji; Lihua Qiu; Benjamin K Tsang; Wen Di
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-24       Impact factor: 4.553

Review 2.  Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports.

Authors:  Rahul P Patel; Madhur D Shastri; Long Chiau Ming; Syed Tabish R Zaidi; Gregory M Peterson
Journal:  Front Pharmacol       Date:  2018-06-05       Impact factor: 5.810

3.  In vitro effects of Apixaban on 5 different cancer cell lines.

Authors:  Luigina Guasti; Alessandro Squizzato; Paola Moretto; Davide Vigetti; Walter Ageno; Francesco Dentali; Andrea M Maresca; Leonardo Campiotti; Anna M Grandi; Alberto Passi
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

4.  Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients.

Authors:  Sandra Nezi-Cahn; Isabel Sicking; Kathrin Almstedt; Marco Battista; Anne-Sophie Heimes; Slavomir Krajnak; Joscha Steetskamp; Annette Hasenburg; Marcus Schmidt
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-06-05       Impact factor: 2.915

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.